Abstract
Drugs acting at dopamine (DA) receptors provide an important therapeutic approach in the treatment of various cardiovascular emergencies [1–3]. Peripheral dopamine receptors are classified into two distinct subtypes, namely DA-1 and DA-2 [1–3]. Whereas DA, in addition to stimulating both DA-1 and DA-2 receptors, also activates α- and β-adrenoceptors, there are compounds available which preferentially activate either DA-1 and/or DA-2 receptors and do not stimulate a- and β-adrenoceptors. The major cardiovascular consequence following stimulation of DA receptors include decreases in cardiac afterload or peripheral vascular resistance, increases in cardiac index, mesenteric and renal blood flows as well as natriuresis and diuresis. The dopaminergic drugs currently available for the treatment of cardiovascular emergencies include dopamine, fenoldopam and dopexamine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Lokhandwala MF, Hegde SS (1991) Cardiovascular pharmacology of adrenergic and dopaminergic receptors: Therapeutic significance in congestive heart failure. Am J Med 90 (Suppl 5B): 5–9
Chen CJ, Lokhandwala MF (1992) Dopamine receptor agonists in cardiovascular pharmacotherapy. Ind J Pharmacol 24: 72–81
Lokhandwala MF, Chen CJ (1993) Peripheral dopamine receptors. In: Niznik HB (ed) Dopamine receptor function and pharmacology. Marcel Dekker, New York, pp 89–92
Hegde SS, Lokhandwala MF (1988) Involvement of cyclic-AMP in the hypotensive response to fenoldopam but not to quinpirole in the anesthetized rat. J Auton Pharmacol 8: 63–88
Felder CC, McKelvey AM, Gitler MS, Eisner GM, Jose PA (1989) Dopamine receptor subtypes in renal brushborder and basolateral membranes. Kidney Int 36: 183–193
Lokhandwala MF, Amenta F (1991) Anatomical distribution and function of dopamine receptors in the kidney. FASEB J 5: 3023–3030
Bertorello AM, Katz AI (1993) Short term regulation of renal Na-K-ATPase activity: Physiological relevance and cellular mechanisms. Am J Physiol 265: F743–F755
Vyas SJ, Jadhav AL, Eichberg J, Lokhandwala MF (1992) Dopamine receptor-mediated activation of phospholipase-C is associated with natruresis during high sodium intake. Am J Physiol 262: F494–F498
van Veldhuisen DK, Gribes ARJ, deGraeff PA, Lie KI (1992) Effects of dopaminergic agents on cardiac and renal function in normal man and in patients with congestive heart failure. Int J Cardiol 37: 293–300
Maskin CS, Ocken S, Chadwick B, LeJemtel TH (1985) Comparative systemic and renal effects of dopamine and angiotensin-converting enzyme inhibition with enalaprilat in patients with heart failure. Circulation 72: 846–852
Szerlip HM (1991) Renal-dose dopamine: Fact and fiction. Ann Intern Med 115: 153–154
Linder A (1983) Synergism of dopamine and furosemide in diuretic-resistant oliguric acute renal failure. Nephron 37: 39–42
Lokhandwala MF (1991) Effects of dopamine receptor agonists on cardiovascular and renal function. In: Vincent JL (ed) Update in intensive care and emergency medicine, Vol 14. Springer-Verlag, Berlin, pp 74–80
Nichols AJ, Koster PF, Brooks DP, Ruffolo RR Jr (1992) Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog. J Pharmacol Exp Therapy 260: 269–274
Wang YX, Gellai M, Brooks DP (1992) Dopamine DA1 receptor agonist, fenoldopam, reverses glycine-induced hyperfiltration in rats. Am J Physiol 262: F1055–F1060
Brodde OE (1991) Beta 1- and beta 2-adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203–242
Vincent JL (ed) (1991) Towards improving vital organ function: Assessing the role of dopexamine hydrochloride in intensive care medicine. Clin Intensive Care 2 (Suppl): 5–54
Boyd O, Bennett ED (1992) Effects of dopexamine hydrochloride in a porcine sepsis model and in high-risk peri-operative surgical patients. Clin Intensive Care 3 (Suppl): 32–36
Gray PA, Bodeham AR, Park GR (1991) A comparison of dopexamine and dopamine to prevent renal impairment in patients undergoing orthotopic liver transplantation. Anaesthesia 46: 638–641
Atallah MM, Saied MMA, El-Diasty TA, Gray PA, Park GR (1992) Renal effects of dopexamine hydrochloride in patients with chronic renal dysfunction. Urol Res 20: 419–424
Chintala MS, Lokhandwala MF, Jandhyala BS (1990) Protective effects of dopexamine hydrochloride in renal failure after acute hemorrhage in anesthetized dogs. J Auton Pharmacol 10 (Suppl): S95–S102
Chintala MS, Moore RJ, Lokhandwala MF, Jandhyala BS (1993) Evaluation of the effects of dopexamine, a novel DA-1 receptor and β2-adrenoceptor agonist, on cardiac function and splanchnic circulation in a canine model of hemorrhagic shock. Naunyn-Schmiedeberg’s Arch Pharmacol 347: 396–400
Jacinto MS, Lokhandwala MF, Jandhyala BS (1994) Studies on pharmacological interventions to prevent free radical (OFC)-mediated toxicity: Effects of Dopexamine, a DA1 receptor and β2-adrenoceptor agonist. Naunyn-Schmiedeberg’s Arch Pharmacol 350: 277–283
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Lokhandwala, M.F., Jandhyala, B.S., Jacinto, S.M. (1995). Dopaminergic Drugs in Cardiovascular Emergencies. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine. Yearbook of Intensive Care and Emergency Medicine, vol 1995. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79154-3_80
Download citation
DOI: https://doi.org/10.1007/978-3-642-79154-3_80
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-58256-4
Online ISBN: 978-3-642-79154-3
eBook Packages: Springer Book Archive